Anika Therapeutics

Anika Therapeutics, Inc. is an orthopedic and regenerative medicines company, which develops, manufactures and commercializes therapeutic products for pain management, tissue regeneration, and wound healing. Its products are based on hyaluronic acid, a natural chemical occurring, biocompatible polymer found throughout the body. It offers therapeutic products which include orthobiologics, dermal, ophthalmic, surgical, ophthalmic and veterinary. The company was founded in 1992 and is headquartered in Bedford, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Anika Therapeutics reports strong Q4 earnings, eyes growth opportunities

Anika Therapeutics delivered strong financial performance in Q4 2022, with revenue growth and strategic investments driving growth targets for 2023. The company is focused on product launches, expanding its portfolio, and preparing for the launch of the RevoMotion Reverse Shoulder System.
While facing challenges such as higher stock-based compensation and lower EBITDA expected in 2023, Anika remains optimistic about the value inflection point in 2023. The company's emphasis on growth initiatives and commercial optimization positions it for future opportunities.

Anika Therapeutics reports growth in core segments and strategic investments

Anika Therapeutics showed positive revenue growth in Q1, driven by core business segments.
Despite a net loss, Anika is strategically positioning itself as a global leader in joint preservation.
Investments in new products and regulatory progress with Cingal indicate a focus on innovation and expansion.
Maintaining strong gross margins amidst increased operating expenses highlights operational efficiency.

Anika Therapeutics posts robust Q2 results, eyes growth opportunities

Anika Therapeutics reported strong Q2 results, raising its revenue outlook for 2023.
Despite international challenges, the company sees opportunities for growth in key segments.
Progress in FDA approvals, partnerships, and new product launches position Anika for future success.
Maintaining a focus on innovation and market expansion will be crucial for sustained growth.

Anika Therapeutics raises guidance on strong Q3 performance and outlook

Anika Therapeutics showcased robust growth in key segments, leading to an optimistic outlook for the year. Despite challenges in restructuring sales operations, the company is well-positioned for continued success with a focus on profitability and new product launches.

Anika Therapeutics exceeds Q4 expectations, eyes Hyalofast's U.S. potential

Anika Therapeutics delivered robust financial performance, focusing on driving new products for growth and operational efficiency. The company aims to accelerate profitability targets and is on track with product launches, making strategic adjustments based on feedback.

Anika Therapeutics reports Q1 revenue growth and strategic product advancements

Anika Therapeutics demonstrated solid financial performance in Q1 2024, driven by revenue growth, cost reduction initiatives, and positive market feedback on key products.
While facing challenges such as FDA approval requirements and leadership transition, the company's strengths in product portfolio and distribution agreements position it well for future growth.
Opportunities in FDA designations, revenue growth expectations, and operational improvements present avenues for Anika to enhance market presence and financial performance in the coming quarters.

Anika Therapeutics reports Q3 revenue, focuses on core products

Anika Therapeutics faces challenges with workforce reduction and financial losses
However, strategic focus on core HA products and revenue reclassification show promise
Opportunities lie in revenue growth in the commercial channel and long-term investments
Overall, Anika Therapeutics aims for sustainable growth and value creation

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Anika Therapeutics, Inc. is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Its products are based on hyaluronic acid, a natural chemical occurring, biocompatible polymer found throughout the body. It offers therapeutic products which include orthobiologics, dermal, ophthalmic, surgical, ophthalmic and veterinary. The company's main focus is on high opportunity spaces within orthopedics, including Osteoarthritis Pain Management, Regenerative Solutions, Sports Medicine and Arthrosurface Joint Solutions, and its products are efficiently delivered in key sites of care, including ambulatory surgery centers. Anika Therapeutics was founded in 1992 and is headquartered in Bedford, MA.

BEDFORD, Mass., April 05, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Dr. Cheryl Blanchard, President and Chief Executive Officer and Michael Levitz, Executive Vice President, Chief Financial Officer and Treasurer, will present at the 20th Annual Needham Virtual Healthcare Conference on Thursday, April 15, 2021 at 3:45 p.m. ET.

Anika to Participate in the 20th Annual Needham Virtual Healthcare Conference

BEDFORD, Mass., March 11, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Dr. Cheryl Blanchard, President and Chief Executive Officer and Michael Levitz, Executive Vice President, Chief Financial Officer and Treasurer, will present at the Sidoti Spring Virtual Investor Conference on Thursday, March 25, 2021 at 8:30 a.m. ET.

Anika to Participate in the Sidoti Spring Virtual Investor Conference

Anika Therapeutics, Inc. (ANIK) CEO Cheryl Blanchard on Q4 2020 Results - Earnings Call Transcript

Anika (ANIK) delivered earnings and revenue surprises of -1000.00% and -2.40%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Anika Therapeutics (ANIK) Reports Q4 Loss, Lags Revenue Estimates

Shares of Anika Therapeutics (NASDAQ:ANIK) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 72.09% year over year to $0.12, which beat the estimate of ($0.01).

Recap: Anika Therapeutics Q4 Earnings

Completed Transformative Year with Q4 2020 Revenue Up 10% Year-Over-Year, Full Year 2020 Revenue up 14% Well Positioned for Growth in 2021

Anika Reports Fourth Quarter and Year-End 2020 Financial Results

BEDFORD, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care, today announced that the Company plans to issue its fourth quarter and year-end 2020 financial results after the close of the market on Thursday, March 4, 2021 and hold its investor conference call and webcast on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights.

Anika to Issue Fourth Quarter and Year-End 2020 Financial Results on Thursday, March 4, 2021

Laureate Education

Nuance Communications

Varex Imaging

Just like selecting good and undervalued stocks on a regular basis can make you rich, identifying and proactively getting rid of toxic stocks is also crucial to maximizing portfolio returns.

Keep These 4 Toxic Stocks Away From Your Portfolio

Anika Therapeutics (ANIK) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Anika Therapeutics (ANIK) Surges: Stock Moves 6.6% Higher

Anika Therapeutics, Inc. (ANIK) CEO Cheryl Blanchard on Q3 2020 Results - Earnings Call Transcript

Anika Therapeutics, Inc.'s (ANIK) CEO Cheryl Blanchard on Q3 2020 Results - Quick Version Earnings Call Transcript

Revenue Increased 7% Year-over-Year to $ 31.7 Million Repaid $25 M illion of Outstanding Credit Facility Continued Expansion of Joint Preservation Product Portfolio

Anika Reports Third-Quarter 2020 Financial Results

Anika (ANIK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Anika Therapeutics (ANIK) to Report a Decline in Earnings: What to Look Out for

BEDFORD, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care, today announced that the Company plans to issue its third quarter 2020 financial results after the close of the market on Wednesday, November 4, 2020 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights.

Anika to Issue Third Quarter 2020 Financial Results and Business Highlights on Wednesday, November 4, 2020

System designed to alleviate pain and restore function and mobility of the wrist joint System designed to alleviate pain and restore function and mobility of the wrist joint

Anika Announces FDA 510(k) Clearance for its WristMotion® Total Arthroplasty System for the Replacement of Painful Wrist Joints

Illumina

ANIK vs. ILMN: Which Stock Is the Better Value Option?

ANIK vs. ILMN: Which Stock Should Value Investors Buy Now?

Board Chair Joseph Bower, D.B.A. announces intention not to stand for re-election at 2021 Annual Meeting  Jeffery Thompson succeeds Dr. Bower as Chair of the Board

Anika Announces Appointment of Jack Henneman and Stephen Richard to Board of Directors

NeoGenomics

ANIK vs. NEO: Which Stock Is the Better Value Option?

Alkermes

ANIK vs. ALKS: Which Stock Is the Better Value Option?

ANIK vs. ALKS: Which Stock Should Value Investors Buy Now?

Seasoned financial executive brings broad medical device industry experience and track record of value creation Seasoned financial executive brings broad medical device industry experience and track record of value creation

Anika Appoints Michael Levitz as Chief Financial Officer

ANIK or ALKS: Which Is the Better Value Stock Right Now?

Anika Therapeutics, Inc.'s (ANIK) CEO Cheryl Blanchard on Q2 2020 Results - Earnings Call Transcript

Anika Therapeutics: After A Stormy Period, Orthopedic Specialist Looks Set Fair

Anika (ANIK) delivered earnings and revenue surprises of 142.86% and 83.37%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Anika Therapeutics (ANIK) Q2 Earnings and Revenues Surpass Estimates

Increased Total Revenue 1% Year-over-Year to $30.7 Million  Accelerated the Commercial Integration of Parcus Medical and Arthrosurface Organizations  Launching Seven FDA-Cleared Orthopedic and Sports Medicine Products Through Q3 2020

News for Anika Therapeutics Stock (ANIK)